<DOC>
	<DOCNO>NCT00605657</DOCNO>
	<brief_summary>This study test whether valproic acid ( Depakote [ Registered Trademark ] ) shrink enlarge lymph gland spleen patient autoimmune lymphoproliferative syndrome ( ALPS ) . Depakote use 30 year treat various medical disorder adult child , include migraine headache , seizure psychiatric disorder . In animal study , effective shrink lymph node spleen animal condition similar ALPS . People ALPS 2 70 year age enlarge spleen lymph gland least 1 year may eligible study . Participants take Depakote tablet liquid sprinkle food twice day 16 week . The drug dose increase slowly first 3 4 week maximum tolerate dose reach . Blood test do 2 , 4 , 6 , 8 10 week start drug 1 week drug stop check treatment side effect . Valproic acid blood level check drug escalation , half way therapy , end treatment . A physical examination CT scan ( ultrasound abdomen patient undergo CT ) do start treatment end 16-week treatment period evaluate response treatment . Patients tolerate treatment well show shrinkage lymph gland spleen may offer extend treatment 1 year consultation primary physician . During extended treatment period , blood test do home every 6 8 week monitor drug side effect . Follow evaluation visit schedule NIH Clinical Center every 3 month extend treatment period 3 , 6 , 12 month treatment end .</brief_summary>
	<brief_title>Valproic Acid ( DepakoteRegistered Trademark ) Treat Autoimmune Lymphoproliferative Syndrome ( ALPS )</brief_title>
	<detailed_description>The Autoimmune Lymphoproliferative Syndrome ( ALPS ) inherit disease associate defect lymphocyte apoptosis lead lymphoproliferation autoimmunity . Although , immunosuppressive treatment many complication , currently safe effective therapy syndrome . Valproic acid recently use histone deacetylase ( HDAC ) inhibitor induce apoptosis malignancy incorporate part hematology/oncology clinical trial . A pilot study conduct safety efficacy drug valproic acid ( Depakote [ R ] ) treatment ALPS . Twelve subject ALPS , treat initially 4 month twice-daily administration valproic acid escalate dos adjust weight , close monitoring toxicity side effect include laboratory parameter related drug . The effect valproic acid treatment lymph node and/or spleen size assess computerized tomography scan , ultrasound physical examination . If valproic acid effective reduce size lymph node and/or spleen size define study design , subject may offer option continue therapy valproic acid 1 year . The effect treatment laboratory feature specific ALPS also assess . Evaluating effect valproic acid clinical laboratory parameter help determine drug demonstrate sufficient activity warrant study large randomize control trial .</detailed_description>
	<mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
	<mesh_term>Hypersplenism</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All subject must fulfill publish criterion diagnosis ALPS ( document nonmalignant lymphadenopathy and/or splenomegaly least 1year duration ; great than1 % TCR alpha/beta+ CD4CD8 T cell peripheral blood ) . This must include clinically document lymphadenopathy involve 2 node 1 regional group node measure great 2cm size and/or palpable spleen . 2 . Age great equal 2 year less equal 70 year . 3 . Must personal primary care physician willing follow protocol require evaluation study period . 4 . Must willing sign consent form . 5 . Patients immunosuppression ( e.g. , corticosteroid , mycophenolate mofetil , azathioprine , cyclophosphamide ) eligible dose immunosuppressive drug stable least 3 month prior enrollment hematologic parameter meet exclusion criterion ( 1 ) outline . EXCLUSION CRITERIA : 1 . A hemoglobin concentration le 8 gm/dL , platelet count le 75 K/mm ( 3 ) , absolute neutrophil count le 500/mm ( 3 ) , study entry . 2 . Liver disease determine alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin 2.5 time great upper limit normal . 3 . History pancreatitis clinical feature and/or laboratory abnormality last 12 month . 4 . Renal dysfunction determine calculated urine creatinine clearance le 70 mL/min/1.73 ( 2 ) child less 60 mL/min adult , use Schwartz formula Levy formula base serum creatinine . 5 . Patients clinically suspect suffer urea cycle disorder exclude . 6 . Patients history seizure disorder and/or already receive valproic acid exclude . 7 . Sensitive ever allergic reaction Depakote . 8 . Not able abstain alcohol length study . 9 . Pregnancy . Female adults adolescent attain menarche must negative pregnancy test study entry commit use acceptable method barrier hormonal contraception ( e.g. , condom , diaphragm , oral contraceptive , long act progestin agent ) sexually active study 3 month last dose valproic acid . 10 . Lactating mother breast feed baby eligible . 11 . ALPS patient treat bone marrow toxic chemotherapy regimens NonHodgkin 's lymphoma malignancy eligible pilot study . 12 . Unwilling unable comply need periodic blood test monitor possible side effect treatment , major requirement study exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ALPS</keyword>
	<keyword>Valproic Acid</keyword>
	<keyword>Lymphadenopathy</keyword>
	<keyword>Splenomegaly</keyword>
	<keyword>Histone Deacytelase ( HDAC ) Inhibitor</keyword>
	<keyword>Autoimmune Lymphoproliferative Syndrome</keyword>
</DOC>